Lanthio Pharma, a MorphoSys AG company, Rozenburglaan 13B, 9727 DL, Groningen, the Netherlands.
Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 7, 9747 AG, Groningen, the Netherlands.
Mol Med. 2020 Aug 17;26(1):80. doi: 10.1186/s10020-020-00211-0.
Infection of lung cells by the corona virus results in a loss of the balance between, on the one hand, angiotensin II-mediated stimulation of the angiotensin II type 1 receptor and, on the other hand, stimulation of the angiotensin II type 2 receptor and/or the Mas receptor. The unbalanced enhanced stimulation of the angiotensin II type 1 receptor causes inflammation, edema and contributes to the pathogenesis of severe acute respiratory distress syndrome. Here we hypothesize that stable, receptor-specific agonists of the angiotensin II type 2 receptor and of the Mas receptor are molecular medicines to treat COVID-19 patients. These agonists have therapeutic potential in the acute disease but in addition may reduce COVID-19-associated long-term pulmonary dysfunction and overall end-organ damage of this disease.
冠状病毒感染肺细胞会导致血管紧张素 II 介导体表面 1 型受体的刺激与血管紧张素 II 型 2 受体和/或 Mas 受体的刺激之间失去平衡。血管紧张素 II 型 1 受体的不平衡增强刺激会引起炎症和水肿，并有助于严重急性呼吸窘迫综合征的发病机制。在这里，我们假设血管紧张素 II 型 2 受体和 Mas 受体的稳定、受体特异性激动剂是治疗 COVID-19 患者的分子药物。这些激动剂在急性疾病中有治疗潜力，但除此之外，还可能降低 COVID-19 相关的长期肺功能障碍和这种疾病的整体终末器官损伤。
